Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC
NCT07802834Phase 2Not yet recruiting
- Sponsor
- Stanford University
- Start
- Nov 2026
- Primary completion
- Dec 2028
01
Overview
Phase 2, open-label trial of zipalertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Stanford University. Primary endpoint: Molecular response rate at 12 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
zipalertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07802834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07802834.